APTIVUS
LOE ApproachingNDAORALSOLUTIONPriority Review
Approved
Jun 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
APTIVUS by Boehringer Ingelheim is 12. First approved in 2008.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APTIVUS (tipranavir) is an oral protease inhibitor antiretroviral medication co-administered with ritonavir for HIV-1 treatment. It works by inhibiting HIV protease, preventing viral replication in treatment-experienced patients. The drug is indicated for HIV-positive subjects with evidence of viral replication despite prior antiretroviral therapy.
$0.001BPart D
LOE ApproachingDeclining
Minimal commercial momentum with only 577 Medicare Part D claims in 2023, signaling a mature product nearing exclusivity loss with likely small, specialized team.
Mechanism of Action
12.1 Mechanism of Action Tipranavir is an antiretroviral drug [ see ]. 12.2 Pharmacodynamics ECG Evaluation The effect of APTIVUS/ritonavir on the QTcF interval was measured in a study in which 81 healthy subjects received the following treatments twice daily for 2.5 days: APTIVUS/ritonavir (500…
Worked on APTIVUS at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.